Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.4 CHF | +1.25% | +0.37% | +14.31% |
05-03 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
04-09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.31% | 532M | |
+25.69% | 47.9B | |
+47.75% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Pfizer to Pay $1.3 Million Milestone Payment to Basilea For Asia-Pacific Sales of Cresemba